- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03972865
Cardiovascular Consequences in Intense and Extended Physical Exercise (PHILIPPIDES)
Cardiovascular Consequences and Risk of Ventricular Rhythm Disorder in Intense and Extended Physical Exercise
Study Overview
Status
Intervention / Treatment
Detailed Description
Background and rationale:
While regular and moderate physical activity is strongly recommended in reducing cardiovascular risk, the scientific community questions the potentially harmful effects of prolonged and intense physical activity. In the short term, functional ultrasonographic changes (systolic and diastolic) and disturbances of biomarkers such as troponin are reported in participants in long-term endurance trials, assuming myocardial remodeling and transient tissue damage leading to suffering or "heart fatigue". These constraints could, to the extreme, favor the development of arrhythmogenic foci at the atrial and ventricular stages, and at least, be responsible for a sudden death of the athlete. Adaptations of the athlete's heart have mainly been studied in the left ventricle but more and more studies are studying the right ventricle (RV). These alterations are nevertheless poorly characterized and the consequences including the risk of ventricular rhythm disorder have not been studied.
Primary and Secondary Objectives:
The primary objective is to test the existence of a relationship between RV functional abnormalities induced by intense and prolonged exercise, and the occurrence of ventricular ectopic beats (VEB) from RV. The secondary objectives are to characterize the respiratory impairment of this type of course and to study its relation with the functional anomalies of the RV and the occurrence of VEB.
Methodology:
This is a prospective study including male triathletes participating in the long-distance triathlon of Embrun in August 2019 (3.8 km of swimming, 188 km of cycling and 42.2 km of running), aged between 20 to 54 years years old. The criteria for non-inclusion are subjects with a history of heart disease or rhythm disorder or who have one or more cardiovascular risk factors, taking cardiovascular treatment or using doping products. The primary endpoint is the degree of correlation between course induced right ventricular functional abnormalities (by the use of 2d-strain ultrasound imaging) and the number of VEB from RV during or up to 72 hours after the race.
Procedure:
The study will take place during the Embrun triathlon in August 2019. There will be 2 evaluations: one before the race and one 30 minutes after the race, where will be carried out a self-questionnaire, a clinical examination, EKG, echocardiography and spirometry. An EKG holter in the form of a patch, adapted to sport and submersible practice, will be put in place 24 to 48 hours before the race and left until 72 hours after the race.
Outcomes / perspectives:
Characterizing the effects of a long-distance triathlon on cardiac contractile function and evaluating the athlete's rhythmic risk would make it possible to better understand these pathophysiological consequences and ultimately better detect athletes at risk of sudden death.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hérault
-
Montpellier, Hérault, France, 34090
- Arnaud de Villeneuve, CHU
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male sex
- Age between 20 to 54 years old
- Participating in the triathlon of Embrun 2019
- Collection of free and informed consent given verbally and in writing.
Exclusion Criteria:
- History of heart disease
- History of cardiac rhythm disorder.
- Subject with 1 or more cardiovascular risk factors (tobacco, diabetes, hypertension, BMI> 30).
- Cardiac, vascular or respiratory treatment(s).
- Use of substances on the list of doping products of the French Anti-Doping Agency (https://www.afld.fr/wp-content/uploads/2018/01/Liste-des- prohibitions-2018.pdf)
- Subject in relative exclusion period compared to another protocol or for which the annual amount of the maximum indemnities of 4500 € has been reached.
- Participation of the subject in another study
- Subject not affiliated to a social security scheme, or not a beneficiary of such a scheme.
- Pregnant or nursing woman, patient unable to give her protected primary consent, vulnerable persons (art.L.1121-6, L.1121-7, L.1211-8, L.1211-9)
- Subject deprived of liberty by judicial or administrative decision
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Participants of the race
Participants of the race are healthy triathlete volunteers who will participate in August 2019 in the Embrun (EmbrunMan) long-distance triathlon (Ironman)
|
The EmbrunMan is a long-duration triathlon including 3.8 km of swimming, 188 km of cycling and 42.2 km of running, with a cumulative vertical drop of 4000 metres.
Duration of the race varies between 10 hours and 16hours depending on the athletes' performance.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Test correlation between functional of RV changes after the race and apparition of VEB
Time Frame: 2 or 1 day(s) before the race and 3 days after
|
Test the existence of a correlation between:
|
2 or 1 day(s) before the race and 3 days after
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The secondary objectives are to characterize the respiratory impairment of this type of course and to study its relation with the functional anomalies of the RV and the occurrence of VEB.
Time Frame: 2 or 1 day(s) before the race and 3 days after
|
Test the existence of a correlation between:
|
2 or 1 day(s) before the race and 3 days after
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christophe Hédon, MD, Montpellier University and Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5600
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Right Ventricular Dysfunction
-
University of ChicagoRecruitingHeart Failure | Right Ventricular Dysfunction | Right Ventricular FailureUnited States
-
Semmelweis University Heart and Vascular CenterCompletedRight Ventricular Dysfunction | Right Heart Failure | Right Ventricular Failure | Mitral Valve DiseaseHungary
-
NHS National Waiting Times Centre BoardNHS Greater Glasgow and Clyde; University of Glasgow; Royal London HospitalNot yet recruitingRight Ventricular DysfunctionUnited Kingdom
-
University of MinnesotaRecruitingRight Ventricular DysfunctionUnited States
-
Montreal Heart InstituteOlivier Lachance, MD; Melissa Parent, MD; Patrick Tawil, MD; Etienne Couture, MD... and other collaboratorsCompletedRight Ventricular Dysfunction | Right Heart Failure | Heart; Dysfunction Postoperative, Cardiac SurgeryCanada
-
Centre Hospitalier Universitaire, AmiensRecruitingThoracic Surgery | Right VentricleFrance
-
Jewish General HospitalNot yet recruitingRight Ventricular Dysfunction | Left Ventricular Dysfunction | Quality of RecoveryCanada
-
Azienda Ospedaliera OO.RR. S. Giovanni di Dio e...RecruitingRight Ventricular DysfunctionItaly
-
University of GiessenGerman Research FoundationUnknownRight Ventricular DysfunctionGermany
-
University Hospital DubravaUnknownRight Ventricular Dysfunction | Left Ventricular Dysfunction | Biventricular FailureCroatia
Clinical Trials on EmbrunMan race
-
Centre Hospitalier Universitaire de Saint EtienneRecruiting
-
Sajad Ansari FardUnknownEndodontically Treated TeethIran, Islamic Republic of
-
University Hospital, LinkoepingUnknown
-
University of Wisconsin, MadisonCompleted
-
Children's Hospital Los AngelesRecruitingQuality of Life | Depression, Anxiety | Stress Reaction | Race-related StressUnited States
-
Universitat Jaume IClub Deportivo Marató i Mitja Castelló-Penyagolosa; Fundación Vithas-Nisa; Hospital...Completed
-
Henry Ford Health SystemBeckman Coulter, Inc.CompletedMyocardial Ischemia | Chest PainUnited States
-
The Institute of Molecular and Translational Medicine...RecruitingGenetic Predisposition to DiseaseCzechia
-
Dr. Sharon HassinTel Aviv University; Sheba Medical Center; Bar-Ilan University, IsraelUnknown